For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according to a study published online April 30 in theJournal of Clinical Oncology. (HealthDay) -- For ...
Park et al., "Decursin chemosen- sitizes human multiple myeloma cells through inhibition of STAT3 signaling pathway," Cancer Letters, vol. 301, no. 1, pp. 29- 37, 2011.Kim HJ, Kim SM, Park KR, Jang HJ, Na YS, Ahn KS, et al. Decursin chemosensitizes human multiple myeloma cells ...
Multiple myeloma (MM) is an incurable hematologic malignancy for which autologous hematopoietic stem cell transplantation (HCT) is a standard therapy. The optimal method of stem cell mobilization is not defined. We evaluated intravenous melphalan (60 mg/m), the most effective agent for MM, and G...
1 to receive either 200 mg of intravenous pembrolizumab every 3 weeks coupled with 175 mg/m2of paclitaxel and carboplatin for up to 6 cycles and 400 mg of maintenance pembrolizumab every 6 weeks for an additional 14 cycles, or the same chemotherapy backbone plus placebo and placebo maintenance....
Multiple myeloma (MM) is an incurable hematologic malignancy for which autologous hematopoietic stem cell transplantation (HCT) is a standard therapy. The optimal method of stem cell mobilization is not defined. We evaluated intravenous melphalan (60 mg/m2), the most effective agent for MM, and ...
and a Multiple Myeloma wrist band. All of the above and a free ticket to See Chemo: A Survivors story. Other Ways You Can Help feel free to tell your friends, post the link to your facebook, donate to the American Cancer Society. Looking for more information? Check the project FAQ ...
This strategy can be applied for the treatment of several types of cancer, including lymphoma, leukemia, liver cancer carcinoma of prostate, intestine cancer, myeloma tumor, lymphoma, breast carcinoma, and ovarian cancer [34]. In a study conducted by Quan et al. [35], the authors designed a...
Chemotherapy serves as a main treatment strategy for acute myeloid leukemia (AML), a neoplastic cancer characterized by the accumulation of aberrant immature cells in the bone marrow (BM). To prevent AML relapse, increasing attention is being paid to leukemia cells that can survive chemotherapy. ...
In multiple myeloma (MM) blood-borne malignant plasma cells home to bone marrow (BM), where they accumulate in close contact with stromal cells. Nevertheless, the mechanisms responsible for MM cell chemotaxis are still poorly defined. In the present study we explored the mechanisms involved in th...
PD-L1 vs LAG-3 Expression in Non–Small Cell Lung Cancer Innovative PET Imaging With Cu 64 Anti-CEA in Advanced Rectal Cancer Tivozanib Outperforms ICI Combo in Advanced RCC Han Discusses the Promise of Ga 68 PSMA-11 and BgRT Insights From the AURIGA Trial in Multiple MyelomaRelated...